The Latest Breaking News from Pfizer

Singer is an ‘actual patient’ using the drug Nurtec ODT

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

Scientists debate the benefits of bivalent and monovalent shots

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Pfizer said Tuesday its experimental hemophilia treatment cut down on bleeding episodes in a pivotal study. But Pfizer stock dipped.

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

U.S. health regulators have given full approval to Pfizer’s COVID-19 pill Paxlovid

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,